Firibastat is as efficient as the current standard of care (ramipril) in preventing the degradation of the left ventricular ejection fraction (primary endpoint) after myocardial infarction in full study population Firibastat demonstrated better efficacy compared to ramipril in severe patients with low ejection fraction Firibastat improved blood pressure profile in […]